14. Restructuring Costs (Notes)

3 Months Ended

Sep. 30, 2022

Restructuring and Related Activities Disclosure [Text Block]

RESTRUCTURING COSTS

In February 2021, we announced our strategy-driven restructuring plan in furtherance of our ongoing program to improve operating performance. The restructuring plan primarily impacts our operations in EMEA and includes the elimination of certain positions, the consolidation of certain functions, and the relocation of certain manufacturing operations from EMEA to APAC. The restructuring plan is being implemented in phases and is expected to be substantially complete by mid-2023. The liability of $36.4 million as of September 30, 2022 was recorded in Accrued payroll and employee benefits in the condensed consolidated balance sheets. The amounts reflected in Cost of goods sold, Selling, general and administrative expense and Research and development expense for the three months ended September 30, 2022 were $1.3 million, $2.8 million and $0.5 million, respectively, in the condensed consolidated statements of income (loss). The amounts reflected in Cost of goods sold, Selling, general and administrative expense and Research and development expense for the nine months ended September 30, 2022 were $1.3 million, $3.0 million and $0.3 million, respectively, in the condensed consolidated statements of income (loss). The adjustments to expense recorded were primarily due to extension of termination dates for certain employees and for changes in the estimates of employee termination benefits. From February 2021 to September 30, 2022, total expenses were $69.0 million.

The following table summarizes the activity of our European reorganization restructuring reserves (in millions):


	Life Science		Clinical Diagnostics		Total
Balances as of December 31, 2021:	$	5.2	$	41.9	$	47.1

Adjustment to expense	1.2		3.4		4.6
Cash payments	(2.6)		(6.9)		(9.5)
Foreign currency translation gains	(0.5)		(5.3)		(5.8)
Balances as of September 30, 2022:	$	3.3	$	33.1	$	36.4